Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
February 12, 2018 07:30 ET
|
Actinium Pharmaceuticals
• To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing • Actinium’s executive management and...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
February 08, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
February 07, 2018 09:00 ET
|
Actinium Pharmaceuticals
- Record date established as February 14, 2018 - To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
February 06, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2018 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...
Actinium Pharmaceuticals Announces Rights Offering
February 01, 2018 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product
February 01, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Poster to present additional data showcasing ability of Actinium’s AWE Technology to yield a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma NEW YORK,...
Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions
January 03, 2018 07:30 ET
|
Actinium Pharmaceuticals
Actinium scheduled to present on Monday, January 8, 2018 at 10:00 AM PT NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the...
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
December 27, 2017 09:00 ET
|
Actinium Pharmaceuticals
Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. ...
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
December 05, 2017 07:30 ET
|
Actinium Pharmaceuticals
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...